U.S. markets close in 2 hours
  • S&P 500

    4,278.49
    -26.71 (-0.62%)
     
  • Dow 30

    34,012.99
    -139.02 (-0.41%)
     
  • Nasdaq

    12,946.72
    -155.83 (-1.19%)
     
  • Russell 2000

    1,988.16
    -32.37 (-1.60%)
     
  • Crude Oil

    88.06
    +1.53 (+1.77%)
     
  • Gold

    1,775.60
    -14.10 (-0.79%)
     
  • Silver

    19.74
    -0.35 (-1.74%)
     
  • EUR/USD

    1.0172
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    2.9110
    +0.0870 (+3.08%)
     
  • GBP/USD

    1.2045
    -0.0049 (-0.40%)
     
  • USD/JPY

    135.1900
    +0.9750 (+0.73%)
     
  • BTC-USD

    23,438.57
    -420.80 (-1.76%)
     
  • CMC Crypto 200

    557.36
    -15.45 (-2.70%)
     
  • FTSE 100

    7,515.75
    -20.31 (-0.27%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2022

·1 min read

NEW BRUNSWICK, N.J., July 18, 2022--(BUSINESS WIRE)--Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the third quarter of 2022 of $1.13 per share on the company’s common stock. The dividend is payable on September 6, 2022 to shareholders of record at the close of business on August 23, 2022. The ex-dividend date is August 22, 2022.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005805/en/

Contacts

Press:
Jake Sargent
jsargen3@ITS.JNJ.com

Investors:
Jessica Moore
jmoore29@its.jnj.com

Sarah Wood
swood15@its.jnj.com